ProteaPex Therapeutics, LLC (PxTx) is a Philadelphia based biotech, established in 2011 as a faculty startup from the Philadelphia College of Osteopathic Medicine to research and develop Extracellular Matrix Protection Factors (ECPFs). The ECPFs are a platform technology that can be tailored to several members of the Matrix Metalloprotease (MMP) family. The patented technology boasts development of potential therapeutics for indications in osteoarthritis (OA), periodontal disease, lung fibrosis, wound healing, nonunion fractures and cancer.